Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting

OBJECTIVES: This study evaluated the efficacy and safety of apatinib (an oral small-molecule tyrosine kinase inhibitor targeting VEGFR-2) 250 mg combined with chemotherapy in patients with pretreated metastatic breast cancer in a real-world setting. PATIENTS AND METHODS: A database of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ruyan, Chen, Yifei, Liu, Xiaoran, Gui, Xinyu, Zhu, Anjie, Jiang, Hanfang, Shao, Bin, Liang, Xu, Yan, Ying, Zhang, Jiayang, Song, Guohong, Li, Huiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314217/
https://www.ncbi.nlm.nih.gov/pubmed/37397355
http://dx.doi.org/10.3389/fonc.2023.1076469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314217/
https://www.ncbi.nlm.nih.gov/pubmed/37397355
http://dx.doi.org/10.3389/fonc.2023.1076469

Ejemplares similares